Patents by Inventor Florian SCHWOERER

Florian SCHWOERER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    Publication number: 20240092933
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: November 16, 2023
    Publication date: March 21, 2024
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
  • Antigen binding proteins specifically binding PRAME
    Patent number: 11859009
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: January 2, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Gabriele Pszolla, Martin Hofmann, Meike Hutt, Sebastian Bunk, Felix Unverdorben, Frank Schwoebel, Dominik Maurer, Maike Jaworski, Claudia Wagner, Florian Schwoerer, Heiko Schuster
  • ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    Publication number: 20230357428
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: April 17, 2023
    Publication date: November 9, 2023
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
  • ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    Publication number: 20230091330
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 23, 2023
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER
  • ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    Publication number: 20220372165
    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Meike HUTT, Sebastian BUNK, Felix UNVERDORBEN, Frank SCHWOEBEL, Dominik MAURER, Maike JAWORSKI, Claudia WAGNER, Florian SCHWOERER, Heiko SCHUSTER